SCHEMBL783010

SCHEMBL783010

CC(C)(C)N(CC(=O)O)CC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
EYA2 O00167 1/20 0.41
APP P05067 1/20 0.41
ACE P12821 1/20 0.41
TSHR P16473 3/20 0.39
CYP2C19 P33261 3/20 0.39
ADRA1A P35348 2/20 0.39
KDM4E B2RXH2 2/20 0.39
BLM P54132 2/20 0.39
PMP22 Q01453 2/20 0.39
LMNA P02545 2/20 0.39
HMGCR P04035 1/20 0.39
CHRM1 P11229 1/20 0.39
TBXA2R P21731 1/20 0.39
CHRM2 P08172 1/20 0.39
ADRA2A P08913 1/20 0.39
ALOX15 P16050 1/20 0.39
DRD1 P21728 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14199728 0.90 TDP1 (0.35) TDP1EYA2APPACETSHR
SCHEMBL12981236 0.88 TDP1 (0.33) TDP1EYA2APPACETSHR
SCHEMBL3871128 0.87 FFAR3 (0.36) TDP1EYA2APPACETSHR
SCHEMBL13023088 0.86 TDP1 (0.38) TDP1EYA2APPACETSHR
SCHEMBL10197374 0.85 TDP1 (0.35) TDP1EYA2APPACETSHR
SCHEMBL22291050 0.85 TDP1 (0.35) TDP1EYA2APPACETSHR
SCHEMBL9660711 0.82 TDP1 (0.41) TDP1EYA2APPACETSHR
SCHEMBL26311798 0.81 ADRA1A (0.36) TDP1EYA2APPACETSHR
SCHEMBL6981274 0.81 CA12 (0.35) TDP1EYA2APPACETSHR
SCHEMBL1547956 0.80 ADRA1A (0.43) TDP1EYA2APPACETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185599-B2 Formation and uses of europium WAYNE STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-9717727-B2 Methods of treating and preventing leukemia and other cancers of the blood and bone THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-08-01 US disclosed
US-8883378-B2 Colored curable composition, color filter and method of producing color filter, solid-state image sensor and liquid crystal display device FUJIFILM CORPORATION (JP) 2014-11-11 US disclosed
US-8815478-B2 Colored curable composition, resist liquid, ink for inkjet printing, color filter, method of producing color filter, solid-state image sensor, liquid crystal display, organic EL display, image display device and colorant compound FUJIFILM CORPORATION (JP) 2014-08-26 US disclosed
US-8637215-B2 Colored curable composition, color filter and method of producing color filter, solid-state image sensor and liquid crystal display device FUJIFILM CORPORATION (JP) 2014-01-28 US disclosed
US-20120264039-A1 COLORED CURABLE COMPOSITION, RESIST LIQUID, INK FOR INKJET PRINTING, COLOR FILTER, METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR, LIQUID CRYSTAL DISPLAY, ORGANIC EL DISPLAY, IMAGE DISPLAY DEVICE AND COLORANT COMPOUND FUJIFILM CORPORATION (JP) 2012-10-18 US disclosed
US-20120070856-A1 CROSS-LINKING AGENTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 2012-03-22 US disclosed
US-20110217636-A1 COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2011-09-08 US disclosed
US-7981920-B2 Addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-07-19 US disclosed
US-20100098633-A1 SELECTIVE SEPRASE INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2010-04-22 US disclosed
US-20090082393-A1 New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-26 US disclosed
US-20080234221-A1 Transferring agent into cells; using polypeptides, polynucleotides, antibodies nucleic acids ; tumor suppressor gene; anticancer agents CANJI, INC. (US) 2008-09-25 US disclosed
US-4801722-A FLUORESCENT LABELS EASTMAN KODAK COMPANY (US) 1989-01-31 US disclosed
US-4794191-A FLUORESCENT LABELS EASTMAN KODAK COMPANY (US) 1988-12-27 US disclosed
EP-0068875-B1 FLUORESCENT CHELATES AND LABELED SPECIFIC BINDING REAGENTS PREPARED THEREFROM EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1987-12-23 EP disclosed
US-4637988-A BINDING, ADSORPTION LANTHANIDE CHELATE COMPOUNDS EASTMAN KODAK COMPANY (US) 1987-01-20 US disclosed
EP-0068875-A2 Fluorescent chelates and labeled specific binding reagents prepared therefrom EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1983-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264039-A1 COLORED CURABLE COMPOSITION, RESIST LIQUID, INK FOR INKJET PRINTING, COLOR FILTER, METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR, LIQUID CRYSTAL DISPLAY, ORGANIC EL DISPLAY, IMAGE DISPLAY DEVICE AND COLORANT COMPOUND CDYL, RET, NLRP1 TDP1 2465/4885EYA2 189/4885APP 2855/4885
US-20080234221-A1 Transferring agent into cells; using polypeptides, polynucleotides, antibodies nucleic acids ; tumor suppressor gene; anticancer agents RNASE1, TRDMT1, POLI TDP1 534/4885EYA2 292/4885APP 2725/4885
US-20100098633-A1 SELECTIVE SEPRASE INHIBITORS SLC6A7, DNPEP, PREP TDP1 3266/4885EYA2 3255/4885APP 2080/4885
US-20120070856-A1 CROSS-LINKING AGENTS ORC3, TXN, PROC TDP1 2833/4885EYA2 2624/4885APP 2339/4885
US-11185599-B2 Formation and uses of europium LETM1, CECR2, MCU TDP1 3412/4885EYA2 2531/4885APP 3622/4885
US-20090082393-A1 New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them ACE, AGTR1, AGT TDP1 2205/4885EYA2 3751/4885APP 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.